• Cellular Biomedicine Group Inc., of Palo Alto, Calif., reported positive interim results of its Phase I/IIa trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for knee osteoarthritis. The study, which is testing the safety and efficacy of intra-articular injections of autologous haMPCs to reduce inflammation and repair damaged joint cartilage, showed preliminary findings of improvement (P